Multinational pharmaceutical giant - Novo Nordisk announced China layoffs!

Medical Network September 20th On September 18th, Novo Nordisk's official website released the "Project for Transforming R&D Method", announcing the layoff of 400 people in China and Denmark as part of the restructuring of its R&D department.

In fact, this is not the first layoff of Norderold.

Three months ago, in June this year, there were media reports that Novo Nordisk was considering implementing a cost reduction plan, or it would lay off roughly 3,000 people.

In 2016, in response to the increasingly fierce market competition in the insulin business market, Novo Nordisk plans to help 1,000 people to cut costs. The layoffs cover R&D, sales and administration, and about half of the employees are from Denmark.

Earlier, in November 2015, Novo Nordisk disbanded the nation's education commissioner, and other sales support, education managers and finance positions, about one or two hundred people.

The biggest difference between this layoff and the previous two is that the reason for layoffs is not to mention the cost reduction, but the R&D department restructuring.

It is reported that this layoff reorganization aims to 'accelerate the expansion and diversification of pipelines for serious chronic diseases', increasing investment in transforming biological and technological innovations in core therapeutic areas and new therapeutic areas. Novo Nordisk hopes to concentrate on streamlining the team. Successfully developed a series of chronic disease drugs to share and alleviate the market pressure faced by its core diabetes business.

In addition, Novo Nordisk said it expects to set up four 'transformation research units' focused on finding new therapies and technologies by the end of 2018. At the same time, the company will invest in automation, machine learning and artificial intelligence. Integrating laboratory infrastructure And information technology systems to increase the efficiency of research and development institutions.

Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk, said, 'We need to have the best future skills base in order to demonstrate a higher level of innovation in a broader and more diverse field of chronic diseases. Allocating resources to priority areas. It is a pity that this means that many valuable colleagues will lose their jobs to ensure we have enough innovative research capabilities to support long-term development goals.'

In addition to Novo Nordisk, many pharmaceutical companies are beginning to realize that the company has redundancy in manpower, and lacks competitiveness in big data, artificial intelligence, etc., and has begun to develop vigorously in these areas.

Recently, at the World Internet of Things Expo held in Wuxi, AstraZeneca announced a new medical IoT innovation program and a new development of the 'China Business Innovation Center' after one year.

It is reported that AstraZeneca has signed a number of Internet sites in one breath. enterprise , continuous overweight big data and artificial intelligence in multiple disease The use of the field. Including a strategic cooperation memorandum with Tencent, together with Xunfei Medical to help chronic disease management for chronic patients, and through and Ali health Cooperation, build a retrospective code intelligent patient platform, etc.

In terms of investment and promotion, Alibaba's global executive vice president, International Business and China President Wang Lei told the media, 'We have more than 10,000 employees, and almost 10% of employees are engaged in industrialization related to health IoT innovation. Work, manpower itself is also a huge cost. '

It can be seen that from the research and development to patient services to the whole process solution, many multinational pharmaceutical companies have begun to pay attention to the use of big data and artificial intelligence.

The impact of this on multinational pharmaceutical companies is mainly the adjustment of R&D and marketing departments.

In terms of R&D, we will vigorously develop more promising new areas and integrate old markets with shrinking markets. In the market, we will adjust product promotion models and key product lines with the development of policies and markets.

As a result, related positions will change and adjust. For example, related products reduce the R & D team, reduce the number of sales representatives, and for key products, increase staffing.